CO6260078A2 - Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros - Google Patents
Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otrosInfo
- Publication number
- CO6260078A2 CO6260078A2 CO10019664A CO10019664A CO6260078A2 CO 6260078 A2 CO6260078 A2 CO 6260078A2 CO 10019664 A CO10019664 A CO 10019664A CO 10019664 A CO10019664 A CO 10019664A CO 6260078 A2 CO6260078 A2 CO 6260078A2
- Authority
- CO
- Colombia
- Prior art keywords
- post
- traumatic stress
- patient
- disorder
- benzodiazepina
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 title 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 5
- 229940126062 Compound A Drugs 0.000 abstract 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 4
- 208000024891 symptom Diseases 0.000 abstract 4
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93503607P | 2007-07-23 | 2007-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260078A2 true CO6260078A2 (es) | 2011-03-22 |
Family
ID=40281815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10019664A CO6260078A2 (es) | 2007-07-23 | 2010-02-19 | Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090054403A1 (https=) |
| EP (1) | EP2182952A4 (https=) |
| JP (1) | JP2010534676A (https=) |
| CN (1) | CN101951912A (https=) |
| AU (1) | AU2008279091A1 (https=) |
| CA (1) | CA2707858A1 (https=) |
| CO (1) | CO6260078A2 (https=) |
| MX (1) | MX2010000937A (https=) |
| NZ (1) | NZ583193A (https=) |
| RU (1) | RU2458691C2 (https=) |
| SG (1) | SG183069A1 (https=) |
| WO (1) | WO2009015248A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008279169A1 (en) * | 2007-07-23 | 2009-01-29 | Biotie Therapies, Inc | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder |
| EP3251670A1 (en) * | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| AU2016208412A1 (en) * | 2007-08-06 | 2016-08-18 | Biotie Therapies, Inc. | Methods for treating dependence |
| SMT201700578T1 (it) * | 2009-11-20 | 2018-01-11 | Tonix Pharma Holdings Ltd | Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| SMT202400324T1 (it) | 2013-03-15 | 2024-11-15 | Tonix Pharma Ltd | Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo |
| AU2014354808A1 (en) * | 2013-11-26 | 2016-06-02 | University Of North Texas Health Science Center At Fort Worth | Personalized medicine approach for treating cognitive loss |
| MY186047A (en) | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| RU2614697C1 (ru) * | 2016-04-12 | 2017-03-28 | Общество с ограниченной ответственностью "Нормофарм" | Нейропротекторное средство |
| JOP20190049A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز |
| WO2018222781A2 (en) * | 2017-05-30 | 2018-12-06 | Emerson Paul G | Compositions and methods to regulate hormonal cascades in stress disorders |
| AU2018204843B2 (en) * | 2017-07-05 | 2023-07-27 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating anxiety disorders in patients via renal neuromodulation |
| EP3720856A1 (en) | 2017-12-04 | 2020-10-14 | BIAL - PORTELA & Cª, S.A. | Dopamine-& x392;-hydroxylase inhibitors |
| MX2020006140A (es) | 2017-12-11 | 2020-08-13 | Tonix Pharma Holdings Ltd | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. |
| CN109966281B (zh) * | 2019-04-11 | 2021-04-27 | 北京大学 | PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用 |
| US12521362B2 (en) * | 2019-07-25 | 2026-01-13 | Tokyo University Of Science Foundation | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms |
| CN120882371A (zh) * | 2022-11-30 | 2025-10-31 | 闪烁实验室有限公司 | 使用眼睑跟踪的精神药理学系统和方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| CA2459304A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| EP1336406A1 (en) * | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| CN1662231A (zh) * | 2002-04-24 | 2005-08-31 | 柏树生物科学公司 | 包括应激相关障碍在内的功能性躯体障碍的预防与治疗 |
| WO2005079756A2 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| WO2006096434A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| JP2009500421A (ja) * | 2005-07-06 | 2009-01-08 | セプラコア インコーポレーテッド | エスゾピクロン及び抗うつ薬の組み合わせ |
| WO2008115706A1 (en) * | 2007-03-16 | 2008-09-25 | Emory University | Methods and compositions for treatment of drug addiction |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
-
2008
- 2008-07-23 SG SG2012054540A patent/SG183069A1/en unknown
- 2008-07-23 CA CA2707858A patent/CA2707858A1/en not_active Abandoned
- 2008-07-23 MX MX2010000937A patent/MX2010000937A/es not_active Application Discontinuation
- 2008-07-23 JP JP2010518369A patent/JP2010534676A/ja active Pending
- 2008-07-23 WO PCT/US2008/070948 patent/WO2009015248A1/en not_active Ceased
- 2008-07-23 RU RU2010106014/15A patent/RU2458691C2/ru not_active IP Right Cessation
- 2008-07-23 NZ NZ583193A patent/NZ583193A/en not_active IP Right Cessation
- 2008-07-23 US US12/178,513 patent/US20090054403A1/en not_active Abandoned
- 2008-07-23 CN CN200880108123XA patent/CN101951912A/zh active Pending
- 2008-07-23 EP EP08796518A patent/EP2182952A4/en not_active Withdrawn
- 2008-07-23 AU AU2008279091A patent/AU2008279091A1/en not_active Abandoned
-
2010
- 2010-02-19 CO CO10019664A patent/CO6260078A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2182952A1 (en) | 2010-05-12 |
| AU2008279091A1 (en) | 2009-01-29 |
| CN101951912A (zh) | 2011-01-19 |
| SG183069A1 (en) | 2012-08-30 |
| EP2182952A4 (en) | 2010-09-08 |
| JP2010534676A (ja) | 2010-11-11 |
| NZ583193A (en) | 2012-05-25 |
| CA2707858A1 (en) | 2009-01-29 |
| US20090054403A1 (en) | 2009-02-26 |
| WO2009015248A1 (en) | 2009-01-29 |
| RU2010106014A (ru) | 2011-08-27 |
| MX2010000937A (es) | 2010-06-25 |
| RU2458691C2 (ru) | 2012-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260078A2 (es) | Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros | |
| AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
| AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
| MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
| AR061669A1 (es) | Aplicacion de alta frecuencia de terapia con toxina botulinica | |
| MX2018010852A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2. | |
| AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
| EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| MX2022001623A (es) | Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla. | |
| MX2018011480A (es) | Metodos de intervencion temprana para prevenir o aminorar toxicidad. | |
| ECSP11011275A (es) | Inhibidor de sglt2 para tratar diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, alteración de la tolerancia a la glucosa e hiperglucemia. | |
| AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
| MX2015012520A (es) | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. | |
| CO6220937A2 (es) | Compuestos triciclicos composiciones y procedimientos | |
| DOP2012000155A (es) | Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados | |
| WO2007103373A3 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| BR112014003071A2 (pt) | tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical | |
| AR063470A1 (es) | Terapia combinada | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| ECSP13012551A (es) | Terapia de combinación para tratar infección por hcv. | |
| BR112014012746A2 (pt) | nanoveículos de diagnóstico e/ou terapêutica direcionada por mmp | |
| AR047726A1 (es) | Metodos y reactivos para el tratamiento de trastornos inflamatorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |